Co-promotion

Last updated

Co-promotion is a marketing practice that allows two or more companies to combine their sales force in order to promote a product under the same brand name and price with a single marketing strategy. [1] It is considered as one of the two major forms of joint marketing (Kalb 1988). Co-marketing is the other form and these terms are often confused. [2] It is made through an agreement (the co-promotion agreement) [3] which requires a lot of collaboration between the sales and marketing organisations of both companies. [4] One of the partners usually has a licence to exploit the product and the other partner is the originator or licensor. [1] It helps the less developed areas of a company to be covered by the partner company's strengths and therefore to expand the share of voice in the marketplace for a product. [5] Through co-promotion, a collaborative strategy, the consumer attraction is increased. It is a way co-exploiting products. [4]

Contents

Characteristics

Many collaborative marketing strategies are often confused. The elements that differentiate co-promotion from other marketing practices are the following:

Co-promotion is also known for offering high potential payment, it is the most attractive agreement type for both in and out-licensers compared to other agreements such as co-marketing . [7] Co-promotion agreements also tend to be much more flexible because partners can decide what type of payments they prefer. For example, partners can choose either profit sharing without royalty payments or higher royalties on sales. [7]

The agreement

How it works

Companies seeking a partner identify their areas of strengths and weaknesses and agree to share promotional efforts. [5] The owner of the product usually manufactures it and uses the other company's trademark. The profit on the sales resulting from shared promotional effort is divided according to the amount of effort made by the partners. [8]

Types of agreement

Planning the agreement

Co-promotion agreements symbolise attractive options for the less developed companies that wants to control its product's target but these types of deal structures are much more complex than a company taking full responsibility for development and commercialisation. [6] As a consequence, these collaboration agreements require comprehensive planning, detailed agreements and must consider a number of critical factors such as:

Sharing the product revenues and the expenses by building cost models. Covering financial factors should be done such as allocation of promotional costs and expenses, number and quality of detailing, responsibility for sales force training, and monitoring and auditing of promotion expenses. [6]

A co-promotion example created by the user who wrote the article. Screen Shot 2015-11-03 at 20.12.07.png
A co-promotion example created by the user who wrote the article.

Everyone in the company in any status such as the senior management, the board, the project managers should understand that company capital and wealth will be focused on the partnership. It is important to confirm with your partner that there is a sharing philosophy. [6]

As with any other important business decisions, diverse situations and strategies should be evaluated, companies need to have extensive internal debates to face several principal questions: Why is this proposed deal important for the company? Where do we want this deal to take us? How does the proposed deal fit within the company's short and long-term goals? [6]

When considering a co-promotion deal, a company should keep in mind other possible situations, to maximise long-term flexibility such as retaining co-promotion rights as an option, rather than a firm commitment. [6]

Cost

This graph represents high total payments of co-promotion agreements compared to alternative licensing types. Screen Shot 2015-11-03 at 00.25.11.png
This graph represents high total payments of co-promotion agreements compared to alternative licensing types.

At the beginning stage the average up-front co-promotion payment could be up to $18m, with a potential royalty rate of 25%. At the accomplishment stage these payments has the probability to increase to $53m with a maximum average of royalty rates up to 31%. It is considered as an expensive option for in-licensers as the payments are high in contrast to co-marketing. [7]

However, this technique provides more long-term advantages because high payments has a better possibility to expand the target with combined sales force, thus providing advantages on a long-term basis for companies. [7]

In the pharmaceutical industry

Co-promotion agreements are commonly used by pharmaceutical companies to improve the marketing and product penetration in particular countries. [9] Since the 2000s co-promotion started to play an important role in the pharmaceutical industry.

Co-promotion plays a major role in the pharmaceutical industries because in today's market, pharma companies are in a situation of falling productivity. [8] Accessing to new products through association with biotech companies allows pharma companies to expand their influence and guarantee their success over the market. The industry itself has a complex manufacturing and as a consequence a less competitive market. Therefore, those companies prefer to make co-promotion agreements because they can be able to have a more stable revenue stream which is strategically preferred. Co-promotion is also considered as an advantage for emerging companies in terms of capital infusions, sharing of risks for product development and for regulatory or commercialisation expertise. [8]

While it has been usual for biotech firms to receive between 5%and 10% of the revenues incurred in mutual projects, this number has grown in some cases to around 50% (Zanetti and Steiner 2001). [10]

A specific example

Merck and Agensys had an agreement in order to promote a cancer drug, it has cost $17.5 million in upfront payments and up to $11.5 million over the next year in milestone payments to develop the AGS-PSCA drug for prostate cancer. [6] In this agreement Merck will have the responsibility for commercial manufacture and worldwide clinical development while Agensys will have equal participation in these developments. In addition, Agensys will work on providing a cancer treatment drug at an earlier stage with a smaller chance of risk through milestone payments. The development sharing will help both companies to be more productive. [6]

Top selling drugs in 2015 Screen Shot 2015-10-31 at 15.46.45.png
Top selling drugs in 2015

Other examples

  1. Exelixis in collaboration with GlaxoSmith-Kline (helped to be positioned ad number 2 in the U.S). [8]
  2. Genta in collaboration with Aventis. [10]
  3. Monsanto with Pfizer for Celebex (total upfront payment of $85 million). [8]
  4. Neurocrine in collaboration with Pfizer. [10]
  5. Warner-Lambert and Pfizer for Lipitor. [8]
  6. Glaxo- SmithKline and Janssen for Paxil. [8]
  7. Pharmacia & Upjohn (now part of Pfizer) and Janssen Pharmaceuticals to co-promote Pharmacia's antidepressant Vestra the agreement recovered 27% of the company's total first-half revenues ($6.2 billion), and 44 percent of its total pharmaceutical sales ($3.7 billion). For Pfizer case the agreement was 18% of the company's revenues ($4.4 billion) and totalled $777 million for the first half of 1999. [8]

In other industries

Co-promotion is also used in other industries and other relevant deals were present in the market it is a trend for some companies such as:

  1. The deal between General Motors and Toyota for manufacturing cars. [8]
  2. Siemens and Philips agreed for semiconductors. [8]
  3. Canon and Kodak with photocopiers as well. [8]
  4. Finally City bank and Thai airlines. [11]

Related Research Articles

<span class="mw-page-title-main">Pfizer</span> American multinational pharmaceutical and biotechnology corporation

<span class="mw-page-title-main">Novartis</span> Swiss-American multinational pharmaceutical corporation

Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.

Shire plc was a UK-founded Jersey-registered specialty biopharmaceutical company. Originating in the United Kingdom with an operational base in the United States, its brands and products included Vyvanse, Lialda, and Adderall XR. Shire was acquired by Takeda Pharmaceutical Company on 8 January 2019.

Many countries have measures in place to limit advertising by pharmaceutical companies.

Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology.

<span class="mw-page-title-main">Eisai (company)</span> Japanese pharmaceutical company

Eisai Co., Ltd. is a Japanese pharmaceutical company headquartered in Tokyo, Japan. It has some 10,000 employees, among them about 1,500 in research. Eisai is listed on the Tokyo Stock Exchange and is a member of the Topix 100 and Nikkei 225 stock indices.

<span class="mw-page-title-main">Celgene</span> American biopharmaceutical company

Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).

The pharmaceutical industry is one of the leading industries in the People's Republic of China, covering synthetic chemicals and drugs, prepared Chinese medicines, medical devices, apparatus and instruments, hygiene materials, packing materials, and pharmaceutical machinery. China has the second-largest pharmaceutical market in the world as of 2017 which is worth US$110 billion. China accounts for 20% of the world's population but only a small fraction of the global drug market. China's changing health-care environment is designed to extend basic health insurance to a larger portion of the population and give individuals greater access to products and services. Following the period of change, the pharmaceutical industry is expected to continue its expansion.

The pharmaceutical industry in India was valued at an estimated US$42 billion in 2021 and is estimated to reach $130 billion by 2030. India is the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports. It is also the largest vaccine supplier in the world by volume, accounting for more than 60% of all vaccines manufactured in the world. Indian pharmaceutical products are exported to various regulated markets including the US, UK, European Union and Canada.

Cangene Corporation was a biopharmaceutical company based in Winnipeg, Manitoba, Canada. It was founded in 1984 and specialized in hyperimmunes, contract manufacturing, biopharmaceuticals and biodefense. Cangene was 61% owned by Canadian pharmaceutical giant Apotex and was publicly listed on the TSX under the symbol CNJ.

<span class="mw-page-title-main">Teva Pharmaceuticals</span> Israeli pharmaceutical company

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company with headquarters in Tel Aviv, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals. Teva Pharmaceuticals was the largest generic drug manufacturer, when it was surpassed briefly by US-based Pfizer. Teva regained its market leader position once Pfizer spun off its generic drug division in a merger with Mylan, forming the new company Viatris at the end of 2020. Overall, Teva is the 18th largest pharmaceutical company in the world.

<span class="mw-page-title-main">Daiichi Sankyo</span> Japanese pharmaceutical company

Daiichi Sankyo Company, Limited is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 981.8 billion in revenue in 2019. The company owns the American biotechnology company Plexxikon, American pharmaceutical company American Regent, German biotechnology company U3 Pharma, and recently sold Ranbaxy Laboratories in India. Daiichi Sankyo Co., Ltd. is the producer of Benicar (Olmesartan), an angiotensin II receptor antagonist and top selling drug in the U.S. Global sales of Olmesartan in 2013 were 300.2 billion yen.

The ethics involved within pharmaceutical sales is built from the organizational ethics, which is a matter of system compliance, accountability and culture. Organizational ethics are used when developing the marketing and sales strategy to both the public and the healthcare profession of the strategy. Organizational ethics are best demonstrated through acts of fairness, compassion, integrity, honor, and responsibility.

<span class="mw-page-title-main">Aurobindo Pharma</span> Indian multinational pharmaceutical company

Aurobindo Pharma Limited is an Indian multinational pharmaceutical manufacturing company headquartered in HITEC City, Hyderabad, India. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s area of activity includes six major therapeutic and product areas: antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterologicals, and anti-allergics. The company markets these products in over 125 countries. Its marketing partners include AstraZeneca and Pfizer.

Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington, is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.

Kite Pharma is an American biotechnology company that develops cancer immunotherapy products, with a primary focus on genetically engineered autologous CAR T cell therapy, a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.

Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology. The company is the maker of Botox.

<span class="mw-page-title-main">Hanmi Pharm</span> South Korean pharmaceutical company

Hanmi Pharm Co., Ltd. is a South Korean pharmaceutical company that is headquartered in Seoul.

CSL Vifor is a global specialty pharmaceuticals company in the treatment areas of iron deficiency, dialysis, nephrology & rare disease. It is headquartered in Switzerland and consists of CSL Vifor, Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Sanifit Therapeutics.

References

  1. 1 2 3 4 Currentpartnering.com, (2015). Co-promotion. [Online] Available at: http://www.currentpartnering.com/2014/05/03/co-promotion/ [Accessed 2 Nov. 2015].
  2. ↑ Carter, A. (2007). A Guide To Co-Promotion And Co-Marketing Partnerships In The Pharmaceutical Industry: What's All The Fuss About. [Online] Lesi.org. Available at: http://www.lesi.org/les-nouvelles/les-nouvelles-online/2007/june-2007/2011/08/08/a-guide-to-co-promotion-and-co-marketing-partnerships-in-the-pharmaceutical-industry-what-s-all-the-fuss-about [Accessed 2 Nov. 2015].
  3. ↑ "Co-promotion Agreement". www.sec.gov. Retrieved 2023-11-30.
  4. 1 2 3 4 5 6 Scott, D. (2008). Do you know the pros & cons of co-marketing and co-promotion?. [Online] Celforpharma.com. Available at: "C.E.L.forpharma > Pearls of Wisdom". Archived from the original on 2015-10-23. Retrieved 2015-11-03. [Accessed 2 Nov. 2015].
  5. 1 2 Graben, R. and Sullivan, M. (2011). Special Teams. 1st ed. [ebook] MM&M, p.41. Available at: https://www.imshealth.com/deployedfiles/imshealth/Global/Content/Healthcare/Life%20Sciences%20Solutions/Specialty%20Oncology/Measuring_Specialty_Brand_Growth_MMMarticle.pdf [Accessed 2 Nov. 2015].
  6. 1 2 3 4 5 6 7 8 Garcia, S. (2006). The New Biotech-Pharma Collaborations, Putting the “Co” in Development and Promotion. 1st ed. [ebook] Fenwick & West LLP, p.1. Available at: https://www.fenwick.com/FenwickDocuments/Biotech_Pharma.pdf [Accessed 2 Nov. 2015].
  7. 1 2 3 4 5 DePalma A. (2015). Co promotion gaining at expense of co-marketing. [Online] Pharmaceuticalonline.com. Available at : http://www.pharmaceuticalonline.com/doc/co-promotion-gaining-at-expense-of-co-marketi-0002 [Accessed 2. Nov 2015]
  8. 1 2 3 4 5 6 7 8 9 10 11 12 Carter, A (2007). A Guide to Co-Promotion And Co-Marketing Partnerships In The Pharmaceutical Industry: What's All The Fuss About ? 1st ed [ebook] researchgate p1. Available at : https://www.researchgate.net/publication/260614090_A_Guide_to_co-promotion_and_co-marketing_partnerships_in_the_pharmaceutical_industry_whats_all_the_fuss_about [Accessed 2 Nov. 2015].
  9. ↑ Lawrance, S. (2013). European commission attacks co-promotion agreements - Articles. [Online] Bristows.com. Available at: http://www.bristows.com/articles/european-commission-attacks-co-promotion-agreements [Accessed 2 Nov. 2015].
  10. 1 2 3 Reepmeyer, Gerrit (2006-02-25). Risk-sharing in the Pharmaceutical Industry: The Case of Out-licensing. Springer Science & Business Media. ISBN   978-3-7908-1668-6.
  11. ↑ Thaiairways.co.uk, (2014). Co-Promotion with Citibank. [Online] Available at: http://www.thaiairways.co.uk/en_TH/plan_my_trip/Special_fare/Offers_Booking/citibank.page [Accessed 3 Nov. 2015].
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.